美国食品和药物管理局批准Moderna公司的低剂量COVID-19疫苗用于老年人和有健康状况的人. FDA approves Moderna's lower-dose COVID-19 vaccine for seniors and at-risk adults.

林业发展局批准了现代公司新的低剂量COVID-19疫苗MNexspike,对象是65岁及65岁以上的成年人和12至64岁有基本健康状况的人。 The FDA has approved Moderna's new lower-dose COVID-19 vaccine, mRNA-1273, for adults aged 65 and older and individuals aged 12 to 64 with underlying health conditions. 疫苗只使用了现代疫苗现有疫苗剂量的五分之一,临床试验表明疫苗是安全的,至少与原疫苗一样有效。 The vaccine uses only one-fifth of the dose of Moderna's current vaccine, and clinical trials showed it to be safe and at least as effective as the original. 新的和现有的现代疫苗将于今年秋天供应。 Both the new and existing Moderna vaccines will be available this fall.